Lyra Therapeutics, Inc.

Overview

• IndustrySurgical & Medical Instruments & Apparatus¹
• HeadquartersWatertown, Massachusetts¹
• Incorporated inDE²
• Business address480 Arsenal Way, Watertown, Ma 02472²
• Filer categoryNon-accelerated filer, Smaller reporting company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Lyra Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Lyra Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We occupy one leasehold in Watertown, Massachusetts and two leaseholds in Waltham, Massachusetts. The Watertown lease, as amended, is for office and laboratory space which terminates in April 2027. In Waltham, Massachusetts we have a lease for laboratory, manufacturing and office space, which terminates in July 2033, and a sublease for laboratory and office space, which terminates in November 2032. We do not own any real property. Since the May 2024 RIF, we have been utilizing these leaseholds only partially and we have been attempting to sublease all three to preserve capital.

Item 2 of the 10-K filed Mar 31, 2026.¹¹

Leadership

Who has led Lyra Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMaria Palasis Apr 30, 2020 to now¹²
• ChairHarlan Waksal Feb 18, 2022 to now¹³
• PresidentMaria Palasis Apr 30, 2020 to now¹²
• Chief financial officerJason Cavalier Sep 15, 2021 to now¹⁴
• Chief financial officerR. Don Elsey Apr 30, 2020 to Feb 10, 2021¹⁵

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerJohn R. Bishop, Ph.D. named Jun 9, 2023³²
• Executive Officer, DirectorMaria Palasis, Ph.D. named Apr 26, 2022 to Jun 9, 2023³²
• Executive OfficerRobert Richard, Ph.D. named Apr 26, 2022³³
• DirectorNancy Bradford Snyderman, M.D., FACS named Apr 26, 2022 to Jun 9, 2023³²
• DirectorW. Bradford Smith named Apr 26, 2022 to Jun 9, 2023³²

Former names

• 480 Biomedical, Inc.Oct 30, 2012 to Nov 28, 2016²
• Arsenal Vascular, Inc.Sep 8, 2011 to Nov 8, 2011²
• Arsenal Medical, Inc.Apr 14, 2009 to Aug 12, 2010²
• WMR Biomedical IncMay 9, 2005 to Feb 27, 2009²

Timeline

1. Apr 17, 20268-K Ended a material agreement³⁴
2. Apr 10, 20268-K Ended a material agreement³⁵
3. Mar 16, 20268-K Listing notice or transfer³⁶
4. Feb 27, 20268-K Debt or obligation accelerated³⁷
5. Feb 6, 20268-K Listing notice or transfer³⁸
6. Jan 12, 20268-K Exit or restructuring costs; Executive or director change; Other events³⁹
7. Nov 12, 20258-K Results of operations⁴⁰
8. Sep 4, 20258-K Other events⁴¹
9. Aug 22, 20258-K Listing notice or transfer⁴²
10. Aug 12, 20258-K Results of operations; Regulation FD disclosure⁴³
11. Aug 1, 20258-K Executive or director change⁴⁴
12. Jun 27, 20258-K Entered a material agreement; Unregistered sale of shares; Other events⁴⁵
13. Apr 30, 2020New chief executive Maria Palasis becomes CEO¹²

Calendar

When it reported results

1. Nov 12, 2025Reported quarterly or annual results⁴⁰
2. Aug 12, 2025Reported quarterly or annual results⁴³
3. May 6, 2025Reported quarterly or annual results⁴⁶
4. Mar 13, 2025Reported quarterly or annual results⁴⁷
5. Nov 12, 2024Reported quarterly or annual results⁴⁸
6. Aug 14, 2024Reported quarterly or annual results⁴⁹
7. Apr 30, 2024Reported quarterly or annual results⁵⁰
8. Mar 21, 2024Reported quarterly or annual results⁵¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

247 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 54 major events, 78 insider forms, 37 large holders, 2 private raises, 56 other. The latest 20:

1. May 15, 20264 EDGAR
2. Apr 30, 202615-12G EDGAR
3. Apr 20, 202625 EDGAR
4. Apr 17, 20268-K EDGAR
5. Apr 10, 20268-K EDGAR
6. Apr 3, 20264 EDGAR
7. Apr 3, 20264 EDGAR
8. Mar 31, 202610-K EDGAR
9. Mar 26, 2026EFFECT EDGAR
10. Mar 26, 2026EFFECT EDGAR
11. Mar 26, 2026EFFECT EDGAR
12. Mar 26, 2026S-8 POS EDGAR
13. Mar 26, 2026S-8 POS EDGAR
14. Mar 26, 2026S-8 POS EDGAR
15. Mar 26, 2026S-8 POS EDGAR
16. Mar 26, 2026S-8 POS EDGAR
17. Mar 26, 2026POS AM EDGAR
18. Mar 26, 2026POS AM EDGAR
19. Mar 26, 2026POS AM EDGAR
20. Mar 16, 20268-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

21 open-market trades by officers, directors and large owners since October 2021: 11 buys and 10 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• SABBY MANAGEMENT, LLCSCHEDULE 13G, 1 filing Jan 20, 2026⁵²
• PERCEPTIVE ADVISORS LLCSCHEDULE 13D/A, 10 filings Apr 14, 2022 to Nov 25, 2025⁵³
• CITADEL ADVISORS LLCSCHEDULE 13G/A, 3 filings Jun 12, 2023 to Feb 14, 2025⁵⁴
• Nantahala Capital Management, LLCSCHEDULE 13G/A, 3 filings Feb 14, 2023 to Nov 14, 2024⁵⁵
• Point72 Asset Management, L.P.SC 13G/A, 3 filings Nov 16, 2023 to Nov 14, 2024⁵⁶
• Samsara BioCapital, L.P.SC 13G/A, 2 filings Aug 25, 2023 to Nov 14, 2024⁵⁷
• Venrock Healthcare Capital Partners II, L.P.SC 13G/A, 4 filings Apr 22, 2022 to Nov 14, 2024⁵⁸
• Vestal Point Capital, LPSC 13G/A, 2 filings Feb 13, 2024 to Nov 14, 2024⁵⁹
• PURA VIDA INVESTMENTS, LLCSC 13G/A, 3 filings Nov 8, 2022 to Feb 14, 2024⁶⁰
• NBVM GP, LLCSC 13D/A, 2 filings Apr 22, 2022 to Jun 9, 2023⁶¹
• INTERSOUTH PARTNERS VII L PSC 13G/A, 1 filing Feb 13, 2023⁶²
• Polaris Venture Partners V, L.P.SC 13G/A, 1 filing Feb 7, 2023⁶³
• ArrowMark Colorado Holdings LLCSC 13G/A, 1 filing Feb 14, 2022⁶⁴
• Ikarian Capital, LLCSC 13G/A, 1 filing Feb 14, 2022⁶⁵

Money raised

Private offerings the company reported to the SEC on Form D.

1. May 25, 2023Raised $50 million in a private offering of equity Form D: 24 investors so far Form D
2. Apr 12, 2022Raised $100.5 million in a private offering of equity Form D: 34 investors so far Form D

SEC filer profile

How Lyra Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARLyra Therapeutics, Inc.¹
• CIK0001327273
• Employer ID (EIN)84-1700838¹¹
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company¹¹
• Incorporated inDelaware¹¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address480 Arsenal Way, Watertown, MA 02472¹
• Phone617-373-4600¹
• Shares outstanding1,774,882 shares as of Mar 27, 2026¹¹
• Public float$11.1M as of Jun 30, 2025¹¹
• AuditorBDO USA, P.C., Boston, Massachusetts PCAOB ID 243; no auditor attestation of internal control over financial reporting¹¹
• On EDGAR sinceMay 9, 2005¹
• Filings377 in all: 4 (109), 8-K (68), 3 (26), 10-Q (18), SC 13G/A (17), D (13), SC 13G (12), CORRESP (9)¹
  All 41 form types

  EFFECT (9), SC 13D/A (7), 10-K (6), 144 (6), DEFA14A (6), UPLOAD (6), DEF 14A (5), REGDEX (5), S-8 (5), S-8 POS (5), SCHEDULE 13D/A (5), 424B5 (4), S-3 (4), 424B3 (3), POS AM (3), 10-Q/A (2), 4/A (2), 8-K/A (2), DRS/A (2), PRE 14A (2), S-1 (2), SC 13D (2), SCHEDULE 13G/A (2), 15-12G (1), 25 (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRSLTR (1), REGDEX/A (1), S-1/A (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 31, 2026
  Quarterly report (10-Q) Nov 12, 2025
  Proxy statement (DEF 14A) Apr 4, 2025
  Latest 8-K (8-K) Apr 17, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).¹¹

Risk factors and legal proceedings

The risks Lyra Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 24 risks under these headings, as written.¹¹

• Risks Related to Our Exploration of Strategic Options
• Any potential financial or strategic option we pursue in an effort to maximize shareholder value may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all.
• We are attempting to sublease or assign two of our three leaseholds, which represent significant operating costs, and there can be no assurance that we will accomplish this effort on favorable terms, or at all, which could adversely affect our business, results of operations and financial condition.
• Being delisted from the Nasdaq Stock Market LLC (“Nasdaq”) could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock.
• We could be deemed to be a “shell company”, including after any future asset sales, and as such, we and our stockholders could be restricted in reliance on certain rules or forms.
• Risks Related to Our Financial Position and Need for Additional Capital
• We have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future, and we may never achieve or maintain profitability.
• Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.
• We need significant additional funding in order to complete development of, manufacture, and obtain regulatory approval for our product candidates and commercialize our products, if approved, including the funding necessary to complete a third Phase 3 trial in LYR-210. Moreover, the failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint has made it more difficult for us to raise capital. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, and/or discontinue operations.
• Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.
• Risks Related to Healthcare Laws and Other Legal Compliance Matters
• We are subject to extensive and costly government regulation.

Legal proceedings

From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition.

The opening of Item 3, Legal Proceedings.¹¹